Cargando…
Lenvatinib recruits cytotoxic GZMK+CD8 T cells in hepatocellular carcinoma
Lenvatinib was expected to enhance the effect of immune checkpoint inhibitors (ICIs) for unresectable HCC; however, their combination therapy failed to show the synergy in the phase III clinical trial. METHODS: To elucidate lenvatinib-induced molecular modulation, we performed bulk RNA-sequencing an...
Autores principales: | Yamada, Tomoharu, Fujiwara, Naoto, Kubota, Naoto, Matsushita, Yuki, Nakatsuka, Takuma, Kurosaki, Shigeyuki, Minami, Tatsuya, Tateishi, Ryosuke, Ichida, Akihiko, Arita, Junichi, Hasegawa, Kiyoshi, Koike, Kazuhiko, Fujishiro, Mitsuhiro, Nakagawa, Hayato |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Lippincott Williams & Wilkins
2023
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10351952/ https://www.ncbi.nlm.nih.gov/pubmed/37471053 http://dx.doi.org/10.1097/HC9.0000000000000209 |
Ejemplares similares
-
Improved prognosis of hepatitis C‐related hepatocellular carcinoma in the era of direct‐acting antivirals
por: Fukumoto, Tsuyoshi, et al.
Publicado: (2022) -
Inhibiting SCAP/SREBP exacerbates liver injury and carcinogenesis in murine nonalcoholic steatohepatitis
por: Kawamura, Satoshi, et al.
Publicado: (2022) -
Altered serum acylcarnitine profile is associated with the status of nonalcoholic fatty liver disease (NAFLD) and NAFLD-related hepatocellular carcinoma
por: Enooku, Kenichiro, et al.
Publicado: (2019) -
Cell fate analysis of zone 3 hepatocytes in liver injury and tumorigenesis
por: Kurosaki, Shigeyuki, et al.
Publicado: (2021) -
Lipid Metabolic Reprogramming in Hepatocellular Carcinoma
por: Nakagawa, Hayato, et al.
Publicado: (2018)